ResMed/$RMD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ResMed
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Ticker
$RMD
Sector
Primary listing
NYSE
Employees
10,600
Headquarters
Website
ResMed Metrics
BasicAdvanced
$39B
28.19
$9.51
0.83
$2.19
0.90%
Price and volume
Market cap
$39B
Beta
0.83
52-week high
$293.81
52-week low
$199.92
Average daily volume
911K
Dividend rate
$2.19
Financial strength
Current ratio
3.44
Quick ratio
2.159
Long term debt to equity
13.596
Total debt to equity
14.273
Dividend payout ratio (TTM)
22.19%
Interest coverage (TTM)
2,884.43%
Profitability
EBITDA (TTM)
1,885.867
Gross margin (TTM)
59.99%
Net profit margin (TTM)
27.22%
Operating margin (TTM)
32.79%
Effective tax rate (TTM)
16.50%
Revenue per employee (TTM)
$490,000
Management effectiveness
Return on assets (TTM)
14.02%
Return on equity (TTM)
25.86%
Valuation
Price to earnings (TTM)
28.19
Price to revenue (TTM)
7.643
Price to book
6.58
Price to tangible book (TTM)
15.99
Price to free cash flow (TTM)
23.825
Free cash flow yield (TTM)
4.20%
Free cash flow per share (TTM)
11.253
Dividend yield (TTM)
0.82%
Forward dividend yield
0.90%
Growth
Revenue change (TTM)
9.84%
Earnings per share change (TTM)
37.43%
3-year revenue growth (CAGR)
12.88%
10-year revenue growth (CAGR)
11.85%
3-year earnings per share growth (CAGR)
21.52%
10-year earnings per share growth (CAGR)
14.43%
3-year dividend per share growth (CAGR)
8.06%
10-year dividend per share growth (CAGR)
6.59%
What the Analysts think about ResMed
Analyst ratings (Buy, Hold, Sell) for ResMed stock.
Bulls say / Bears say
ResMed slightly beat Q3 FY25 profit estimates with an adjusted EPS of $2.37 versus the $2.36 consensus and delivered 8% year-over-year revenue growth to $1.29 billion, leading shares to rise 2.6% in after-hours trading as demand for its sleep apnea devices remained robust (Reuters).
Management highlighted that emerging consumer wearables for sleep tracking and GLP-1 weight-loss therapies are expected to drive even greater adoption of ResMed’s devices by expanding the patient funnel, positioning the company to benefit from these complementary trends (Reuters).
ResMed’s stock has outperformed despite earlier GLP-1 concerns, rising 32% from $192 to $253 since July 2024; analysts cited by Barron’s project a 10% annual sales CAGR to $5.3 billion and an 11% EPS CAGR through 2029, while data show CPAP usage is 11% higher among GLP-1 users, underscoring resilient demand (Barron’s).
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
ResMed Financial Performance
Revenues and expenses
ResMed Earnings Performance
Company profitability
ResMed News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ResMed stock?
ResMed (RMD) has a market cap of $39B as of October 20, 2025.
What is the P/E ratio for ResMed stock?
The price to earnings (P/E) ratio for ResMed (RMD) stock is 28.19 as of October 20, 2025.
Does ResMed stock pay dividends?
Yes, the ResMed (RMD) stock pays dividends to shareholders. As of October 20, 2025, the dividend rate is $2.19 and the yield is 0.9%. ResMed has a payout ratio of 22.19% on a trailing twelve-month basis.
When is the next ResMed dividend payment date?
The next ResMed (RMD) dividend payment date is unconfirmed.
What is the beta indicator for ResMed?
ResMed (RMD) has a beta rating of 0.83. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.